The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify tools that medical device sponsors can use in the development and evaluation of medical devices.
Among the many lessons from the COVID-19 pandemic, it’s clear that the future of healthcare belongs to those who can harness science and technology—sometimes rapidly—to improve population health through more efficient and accessible care.
How will you make your company more attractive to investors?
Peter Micca of Deloitte discusses the changes that are happening within the healthcare ecosystem as a whole.
Developing medical devices in general is costly, but there is funding available for companies that are willing to create products specifically for pediatrics.
The agency is creating a virtual center of excellence to expedite the development of combination products.
Companies will soon be able to capitalize on the government’s push to encourage investment in private healthcare facilities.
Having trained biomedical equipment technicians in developing regions can help, but lack of funding is perpetuating a dire situation.
Ernst & Young’s Pulse of the Industry report is out, and once again, it’s not all gloom and doom.